Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance
Annals of Pancreatic Cancer · 2026-08 · 9 · 19-19
DOI: 10.21037/apc-26-0044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pancreatic Cancer, 2026-08. Verfasst von Nayef Abdel-Razeq und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology-Oncology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, USA.
- Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Jacksonville, FL, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Abdel-Razeq, N., Mukhopadhyay, D., & Babiker, H. (2026). Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. Annals of Pancreatic Cancer, 9, 19-19. https://doi.org/10.21037/apc-26-0044
Vancouver
Abdel-Razeq N, Mukhopadhyay D, Babiker H. Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. Annals of Pancreatic Cancer. 2026;9:19-19. doi:10.21037/apc-26-0044
BibTeX
@article{AbdelRazeq2026,
author = {Abdel-Razeq, Nayef and Mukhopadhyay, Debabrata and Babiker, Hani},
title = {Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance},
journal = {Annals of Pancreatic Cancer},
year = {2026},
volume = {9},
pages = {19--19},
doi = {10.21037/apc-26-0044}
}
EUVIMED